- 1 Global variation in tests of cognitive and physical function: analysis of six
- 2 international randomized controlled trials
- 4 Aristeidis H. Katsanos, MD, PhD*^{1,2}; Shun Fu Lee, PhD*¹; Tali Cukierman-Yaffe,
- 5 MD, MSc^{3,4}; Laura Sherlock, MSc⁵; Graciela Muniz-Terrera, PhD⁶; Michele
- 6 Canavan, MD^{7,8}; Raed Joundi, MD, PhD^{1,2}; Mukul Sharma, MD, MSc^{1,2}; Ashkan
- 7 Shoamanesh, MD^{1,2}; Andrea Derix, PhD⁹; Hertzel C. Gerstein, MD^{1,10}; Salim Yusuf,
- 8 MD, PhD^{1,11}; Martin J. O'Donnell, MD^{7,8}; Jackie Bosch, PhD*^{1,12}; William N.
- 9 Whiteley, $MD^{*1,5,13}$
- *equal author contribution
- 13 Affiliations

10

12

- ¹Population Health Research Institute, Hamilton, ON, Canada
- ²Department of Medicine (Neurology), McMaster University, Hamilton, ON, Canada
- ³Department of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine,
- 17 School of Public Health, Tel Aviv University, Herczeg Institute on Aging, Tel Aviv,
- 18 *Israel*
- ⁴Division of Endocrinology & Metabolism, Sheba Medical Centre, Tel Hashomer,
- 20 Ramat Gan, Israel
- ⁵Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- ⁶Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of
- 23 Edinburgh, Edinburgh, UK
- ⁷HRB-Clinical Research Facility, National University of Ireland, Galway, Ireland
- 25 ⁸Department of Geriatric and Stroke Medicine, Galway University Hospital,
- 26 Newcastle Road, Ireland

- ⁹Global Program Head Thrombosis, Bayer Pharmaceuticals, Germany
- 28 ¹⁰Hamilton Health Sciences, Hamilton, ON, Canada
- 29 ¹¹Department of Medicine (Cardiology), McMaster University, Hamilton, ON,
- 30 Canada

40

- 31 ¹²School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada
- 32 ¹³Nuffield Department of Population Health, University of Oxford
- 34 <u>Corresponding author</u>:
- 35 Dr. Aristeidis H. Katsanos, MD, PhD
- 36 Division of Neurology, McMaster University & Population Health Research Institute,
- 37 Hamilton, ON, Canada
- 38 E-mail: ar.katsanos@gmail.com
- 39 Tel: +1-365-888-1441; Fax: +1-905-296-5806
- 41 Number of tables: 0
- *Number of supplemental tables*: 5
- 43 Number of figures: 4
- 44 Number of color figures: 4
- *Number of supplemental figures:* 1
- 46 Number of references: 38
- 47 Word count of abstract: 250

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Total word count of text: 2705 Keywords: cognition; dementia; function; country; cardiovascular **Impact statement** We certify that this work is novel. After analysing data from a large cohort of participants with a history of cardiovascular disease or cardiovascular risk factors, who were recruited in six international randomised controlled trials (RCTs) we found that accounting for country-level factors reduced large differences between world regions in estimates of cognitive impairment, while measures of functional impairment were less variable across world regions. **Key Points** Cognitive and functional test scores in randomized controlled clinical trial cohorts vary widely across world regions. The difference in cognitive test performance was large in comparison to difference in measures of activities of daily living (ADLs). Accounting for country-level factors reduced the differences between world regions in estimates of cognitive impairment. Cognitive test measures were less variable and could be used to better estimate dementia incidence in international studies. Why this study matters? We found that cognitive and functional test scores in RCT cohorts varied widely across world regions. The difference in cognitive test performance was large in comparison to difference in measures of activities of daily living. The impact of

differences on the performance of cognitive tests, which were developed in high-

income countries, creates challenges for harmonized studies of cognitive decline prevention in different world regions. Future studies using the same test around the world could standardise cognitive score by country, and consider using in addition measures of instrumental and basic activities of daily living, where there is less variation across world regions. **Acknowledgments section Conflict of Interest** Authors report no conflicts of interest relevant to this particular manuscript **Author Contributions** AHK, SFL, JB, WNW constructed the study design and prepared the first draft of the manuscript. SFL performed the statistical analyses and prepared the figures. All other authors revised the first manuscript draft for important intellectual content. Sponsor's Role The sponsor had no involvement in the study design, manuscript preparation or decision for publication.

99 100 101 Abstract 102 Background: Better understanding of global variation in simple tests of cognition and 103 function would aid the delivery and interpretation of multi-national studies of the 104 prevention of dementia and functional decline. 105 Methods: We aim to describe the variation in simple measures of cognition and 106 function by world region, study, recruitment centre or individual level factors. In six 107 RCTs that measured cognition with the mini-mental state examination (MMSE), 108 Montreal cognitive assessment (MoCA), and instrumental activities of daily living 109 (IADL) with the Standardised Assessment of Everyday Global Activities (SAGEA), 110 we estimated average scores by global region with multilevel mixed-effects models. 111 We estimated the proportion of participants with cognitive or functional impairment 112 with previously defined thresholds (MMSE\(\leq 24\) or MoCA\(\leq 25\), SAGEA\(\geq 7\)), and with a 113 country-standardised z-score threshold of cognitive or functional score of \leq -1. 114 Results: In 91,396 participants (mean age 66.6±7.8 years, 31% females) from seven 115 world regions, all global regions differed significantly in estimated cognitive function 116 (z-score differences 0.11–0.45, p<0.001) after accounting for individual-level factors, 117 centre and study. In different regions, the proportion of trial participants with 118 MMSE\(\preceq\)24 or MoCA\(\preceq\)25 ranged from 23\(-36\)%; the proportion below a country-119 standardised z-score threshold of ≤1 ranged from 10–14%. The differences in 120 prevalence of impaired IADL (SAGEA≥7) ranged from 2-6% and by country-121 standardised thresholds from 3-6%.

<u>Conclusions:</u> Accounting for country-level factors reduced large differences between world regions in estimates of cognitive impairment. Measures of IADL were less variable across world regions, and could be used to better estimate dementia incidence in large studies.

Introduction

Although international studies of cardiovascular disease prevention usually measure the incidence of major adverse cardiovascular events, they rarely measure functional impairments, such as cognition or the ability to perform everyday activities.^{1, 2} Although they are important to people, these measures of function are hard to measure and standardize internationally. International standardization of measures of function would be needed for drug approval in each country,³ although there are no generally agreed measures.

Culturally appropriate assessments designed to measure cognition or function in individual countries or regions could have internal consistency,⁴ but they are difficult to use at scale or to aggregate between regions. Therefore, using the same assessment tools in all countries is preferable, but requires researchers to recognize and address sources of variation in measuring test performance such as educational attainment, familiarity with testing instruments and the applicability of the functional activities assessed to different regions.^{5, 6} A better understanding of global variation in similar tests of cognition and function, and the sources of variation, would improve measurement, analysis, and interpretation of the results of multi-national studies of cognitive and functional impairment.

We used data from a large cohort of participants with a history of cardiovascular disease or cardiovascular risk factors, in six international randomised controlled trials (RCTs) that assessed antihypertensive, antidiabetic and antithrombotic medications, to describe the variation in simple measures of cognition and function (activities of daily living) by world region. We then sought to determine if variation in the results of cognitive and functional tests between world regions could be explained by study, recruitment centre or individual level factors. We calculated the prevalence of significant cognitive or functional impairment in different world regions, using widely accepted thresholds for cognitive or functional tests, and explored whether country-standardization changed the differences in these estimates between world regions.

Methods

Population

We included participants from six large international cardiovascular prevention RCTs. 7-12 Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) randomly allocated 25,620 participants with coronary artery disease, peripheral artery disease, cerebrovascular disease, or diabetes mellitus with end-organ damage to ramipril (10 mg once daily), telmisartan (80 mg once daily), or a combination of both. 7 Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) randomly allocated 5,926 participants meeting the ONTARGET inclusion criteria but intolerant to ACE inhibitors to either telmisartan (80 mg once daily) or placebo. 8 Outcome Reduction with an Initial Glargine Intervention (ORIGIN) randomly allocated 12,537 participants over the age of 50 with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of 95 mg or less per deciliter [5.3 mmol per liter]) or standard care and to receive n–3 fatty acids or placebo using a 2-by-2

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

factorial design.⁹ The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial randomly allocated 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily) monotherapy, or aspirin monotherapy (100 mg once daily). 10 New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) randomly allocated 7,213 participants with a recent embolic stroke of presumed cardioembolic source to either rivaroxaban (15 mg once daily) or aspirin (100 mg once daily). 11 The Heart Outcomes Prevention Evaluation (HOPE)-3 trial randomly allocated 12,705 participants with intermediate cardiovascular disease risk to receive rosuvastatin (10 mg once daily) or placebo and to receive a combination of candesartan/ hydrochlorothiazide (16/12.5 mg once daily) or placebo, using a 2-by-2 factorial design. 12 In HOPE-3 cognitive assessments were obtained only for those 70 years and older. 12 **Exposures** We grouped countries into seven world regions: North America, Oceania and Western Europe; South America; Eastern Europe and Russia; East Asia; South Asia; Africa; and West Asia (Supplementary Table 1).¹³ Individual participant covariates, measured as continuous variables at either the run-in or randomization visit, were: age in years, body mass index (BMI), waist circumference; systolic and diastolic blood pressure; fasting glucose; and hemoglobin A1c % measured in Diabetes Control and Complications Trial (DCCT) units. We included the following binary variables (yes versus no, excluding missing or unknown) assessed at either the run-in or randomization visit: sex; regular alcohol use (drinking alcohol once or more per week); employment; history of coronary or

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

cerebrovascular disease (transient ischemic attack, stroke, myocardial infarction, angina, heart failure), atrial fibrillation, peripheral arterial disease, hyperlipidemia, hypertension, diabetes mellitus, other non-vascular co-morbidities (cancer, renal dysfunction, liver disease, depression) and history of fall or fracture. Education was categorized as: none or less than primary, primary or secondary, or trade school/college/university. We used the components of the EQ-5D assessment in each trial to derive information on depression and disability.¹⁴ Outcomes For different world regions we presented the results of a cognitive assessment at either the run-in or randomization visit, which was performed using two cognitive tests: the Mini-Mental State Examination (MMSE), a 30-point assessment that addresses seven different cognitive domains (range 0-30, with higher scores meaning better cognition)¹⁵ and the Montreal Cognitive Assessment (MoCA), a 30-point assessment that addresses seven different cognitive domains (range 0-30, with higher scores meaning better cognition). For the MoCA test an additional point is granted to individuals with 12 or fewer years of education. The MMSE was performed in the ORIGIN, TRANSCEND and ONTARGET trials, 7-9 while MoCA was performed in HOPE-3, COMPASS and NAVIGATE ESUS. 10-12 The short version of the MoCA test (maximum score of 12) was completed in HOPE-3, and in our analyses was normalized it to a 30-point scale to allow comparison with other studies. 16, 17 In a subset of trials, we measured the Standardised Assessment of Everyday Global Activities (SAGEA), a 15-item patient-reported outcome measure developed to measure functional status (basic, instrumental, and cognitive activities of daily living) in patients with vascular disease (range 0-45, with higher scores denoting worse

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

regions.

function).¹⁸ The individual items and scoring for the SAGEA is outlined in the Appendix. All tests were administered in the language of participants. Statistical analysis Participants with cognitive or functional assessment available either at run-in or randomization visits were included in the analyses. To account for differences in the study populations we standardised cognitive and functional test scores to the population of each study (study-standardised) or the country's population (countrystandardised). Each participant's raw score was subtracted from the study's or country's specific mean score, and the difference was then divided by the study's or country's specific baseline standard deviation (SD), respectively. Given the comparability in z-scores by age between MMSE and MoCA (Supplementary Figure 1), ¹⁹ we pooled the standardised z-scores of these two tests. We then constructed multilevel mixed-effects models using the studystandardised or country-standardised test scores as the dependent variable, the baseline participant covariates as fixed-effects modifiers and the recruiting centre as a random-effects modifier (allowing testing of between centre heterogeneity). In the unadjusted model we provide the crude estimates; in the age-sex-adjusted model we adjust only for the individual's age and sex and in the maximally-adjusted model we adjust for the individual's age, sex, education, BMI, history of cardiovascular disease, history of cardiovascular risk factors, history of non-cardiovascular diseases and baseline blood pressure. We used the North America, Oceania and Western Europe group as reference, since cognitive and functional tests were developed in countries from these geographical regions, and present the unadjusted and adjusted mean differences and corresponding 95% confidence intervals (95%CI) for other world

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

We estimated the prevalence of cognitive impairment in different world regions with absolute score thresholds for the MMSE (≤24 points) or MoCA (≤25 points). 20, 21 and with a threshold for the study- and country-standardised scores that corresponds to the thresholds of MMSE (24 points or less) or MoCA (25 points or less) in the North America, Oceania and Western Europe group (z≤1.0).²² We then applied this z-score threshold to the other world regions. The same approach was used to estimate the prevalence of functional impairment in different world regions with the absolute threshold of 7 or more points in the SAGEA score, ¹⁸ and then applied the respective z-score threshold for a score of 7 to study- or country-standardised distributions from the other world regions. We calculated the intraclass correlation coefficient (ICC), the proportion of variation within clusters (world regions) over the total variation, for each analysis to estimate the variation of cognitive or functional impairment between the different world regions. The chi-square test was used to test the homogeneity of intraclass correlations. Standard Protocol Approvals, Registrations, and Patient Consents The present work is a post-hoc analysis of previously published randomized controlled clinical trials coordinated by the Population Health Research Institute and was exempt from ethics review board approval. For the collection of data in original studies, informed consent was obtained by primary investigators. **Results** We analyzed data from 91,396 participants in six RCTs from 55 countries recruited between 2001 and 2017 in seven world regions (Supplementary Table 1): North America, Oceania, and Western Europe (39,668); South America (17,923); Eastern Europe and Russia (13,433); East Asia (11,667); South Asia (5,146); Africa (2,273) and West Asia (1,286). Participants had a mean age of 66.6 years (SD 7.8),

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

and 31% were females. Few participants were smokers (17%) or regularly used alcohol (25%). Most participants were educated to primary or secondary level (54%), 39% to higher technical level and 3% had no or less than primary education. Almost a third of participants were employed at study enrolment, 18% had self-reported depression and 9% had self-reported disability based on the EQ-5D questionnaire assessment. More than 90% of the participants had at least one cardiovascular risk factor and 69% had a history of one or more cardiovascular diseases (Supplementary Table 2). Additional participant and country characteristics are provided in Supplementary Table 3. Participants' baseline characteristics demonstrating the greatest variability included alcohol consumption (ranging from 12% in South Asia to 30% in North America, Oceania and Western Europe), self-reported depression (ranging from 12% in Africa to 24% in South America) and self-reported disability (ranging from 3% in East Asia to 18% in South Asia). The prevalence of cardiovascular disease comorbidity at baseline study assessment also varied between the different world regions (Supplementary Table 2). Study-standardised cognitive test scores were lower in people who were older in all world regions except Africa, with large differences between regions (Figure 1A). However, when cognitive scores were standardised to country, older people had consistently lower cognitive scores in all regions, and the variation in z-scores between regions was attenuated (Figure 1B). Cognitive test z-scores standardised for study (adjusted for individual characteristics and centre from which they were recruited), were significantly lower in world regions (p<0.001 for all regions) compared with North America, Oceania and Western Europe (greatest difference for South America z-score mean difference -0.45

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

[95% CI: -0.51 to -0.40]). Standardizing the cognitive test scores for country (adjusting for individual characteristics and centre) reduced variation between world regions. South America, Eastern Europe and Russia, East Asia, Africa and West Asia had modest differences (all z-score mean difference >-0.1, p>0.05) from North America, Oceania and Western Europe, although the difference was slightly greater for South Asia (z-score mean difference: -0.12, 95%CI: -0.22 to -0.02; Figure 2, Supplementary Table 4). Widely used absolute thresholds for MMSE (≤24 points) or MOCA (≤25 points) classified 27% of the overall population with cognitive impairment, with proportions ranging from 23% in North America, Oceania and Western Europe to 36% in South America and West Asia (ICC=0.032, χ^2 =1787). Using the corresponding absolute values z-score threshold of -1.0 (Supplementary Table 5) in study-standardised (not shown) and country standardized cognitive scores led to a lower proportion of participants in each region classified with cognitive impairment (Figure 3). The study-standardized functional SAGEA scores (adjusted for individual characteristics and centre) were lower in Africa (z-score mean difference: -0.32, 95%CI: -0.59 to -0.05) and West Asia (-0.41, 95%CI: -0.63 to -0.19), and higher in East Asia (+0.23, 95%CI: 0.15 to 0.32) compared with North America, Oceania and Western Europe. However, after country standardization (and adjusting for individual characteristics and centre), there were no large or significant differences in SAGEA scores between world regions (all z-score mean differences ≤0.18, p>0.05; Figure 2 & Supplementary Table 4). With a threshold ≥7 points in SAGEA score, 4% of the population was classified with functional impairment, with prevalence rates between regions from 2

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

to 7% (ICC=0.028, χ^2 =89). A z-score of -1.0 in study-standardised distributions and country-standardised distributions resulted in 3% (range 2-6%, ICC=0.024, χ^2 =191) and 4% (range 2-4%, ICC=0.0007, χ^2 =41) prevalence rates of functional impairment, respectively (Figure 4). **Discussion** We found that cognitive and functional test scores in RCT cohorts varied widely across world regions. The difference in cognitive test performance was large in comparison to difference in measures of activities of daily living. These differences in cognitive test scores attenuated modestly after adjusting for individual level factors, or randomisation centre, a surrogate for the socioeconomic status of the area. However, when standardising for country, the differences attenuated substantially, suggesting that unmeasured country-level factors accounted for much of the difference in test performance. Better measurement of educational experience and literacy could further reduce differences in cognitive test performance. Our results are in accordance with previous literature suggesting that there is substantial variation in cognitive test performance between different world regions.^{4, 6,} ¹³ The variability in cognitive test performance between different world regions has previously been associated with modifiable and non-modifiable individual-level factors, ²³⁻²⁷ and the socio-economic status of the area of residence for an individual. ²⁸⁻ The prevalence of cognitive impairment using widely accepted absolute cognitive score thresholds was very large, suggesting factors related to test performance rather than cognitive impairment were responsible for these differences and questioning the suitability of these thresholds for population-based studies. This problem has been identified previously in population-based studies.³² In Sweden, a

MoCA threshold of 25 points or less classified 37.3% of the population as cognitively impaired.³³ A systematic review and meta-analysis of the cross-cultural applicability of MoCA screening for mild cognitive impairment found a wide range of suggested cut-offs both across countries and within regions.³⁴ For example, the cut-off scores of the MoCA were different for five Chinese versions, ranging between 23 and 25 for mild cognitive impairment and between 19 and 24 for dementia.³⁵

In our study, functional measurement showed less variation by region and demonstrate that the use of measures of activities of daily living along with cognitive scores could be used to support a diagnosis of significant cognitive impairment in international studies. Functional measures showed much less regional variation in scores than measures of cognition even before taking into account individual, centres or country-level factors. Tests that use functional measures to measure impairment, although less sensitive might be more consistent between world regions.

Our study had a number of limitations. We analyzed cognitive and functional assessment scores from participants recruited in international large-scale RCTs of cardiovascular interventions. Although these trials were performed in multiple countries and centres around the world, resulting in a multi-ethnic and culturally diverse population, these participants were not representative of their country populations, and our findings are only relevant for trials population. Individuals who agree to participate in RCTs can be very different from the general population on factors beyond the overt inclusion/exclusion criteria. There were substantial differences in the total number of individuals from each of the world regions, leading to increased uncertainty and less precise fit of statistical models for the regions with fewest participants (i.e. West Asia, Africa). Additionally, the number of countries included in each world region differed, e.g. only one country was included for Africa

group and 20 countries were included for North America, Oceania and Western Europe group (Supplementary Table 1). Finally, there was no clinical diagnosis of dementia or mild cognitive impairment, although all patients were able to consent, and none had recorded dementia at baseline.³⁶

The impact of differences on the performance of cognitive tests, which were developed in high-income countries, creates challenges for harmonized studies of cognitive decline prevention in different world regions.³⁷ Universal cut-offs for cognitive decline may lead to erroneous conclusions about an individual's cognitive ability and pose barriers in the interpretation and collation of the results from these tests in international studies.³⁸ New tests could be developed for each country, although this increases study cost and complexity. Future studies using the same test around the world could standardise cognitive score by country, and consider using in addition measures of instrumental and basic activities of daily living, where there is less variation across world regions.

References

386

- 387 1. Iadecola C, Yaffe K, Biller J, et al; American Heart Association Council on
- 388 Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in
- the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of
- 390 Care and Outcomes Research; and Stroke Council. Impact of hypertension on
- 391 cognitive function: a scientific statement from the American Heart Association.
- 392 Hypertension. 2016;68:e67-e94.
- 393 2. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the
- efficacy and safety of statin therapy. Lancet. 2016;388:2532-2561.
- 395 3. Katz R. FDA: evidentiary standards for drug development and approval. NeuroRx.
- 396 2004;1:307-16.
- 4. Prince M, Acosta D, Chiu H, Scazufca M, Varghese M; 10/66 Dementia Research
- 398 Group. Dementia diagnosis in developing countries: a cross-cultural validation study.
- 399 Lancet. 2003;361:909-17.
- 400 5. Max Roser and Esteban Ortiz-Ospina (2016) "Literacy". Published online at
- 401 OurWorldInData.org. Retrieved from: 'https://ourworldindata.org/literacy' [Online
- 402 Resource]
- 6. Ng KP, Chiew HJ, Lim L, Rosa-Neto P, Kandiah N, Gauthier S. The influence of
- 404 language and culture on cognitive assessment tools in the diagnosis of early cognitive
- impairment and dementia. Expert Rev Neurother. 2018;18:859-869.
- 7. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril,
- or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
- 408 8. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with
- 409 cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C,
- et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events

- 411 in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a
- randomised controlled trial. Lancet. 2008;372:1174-83.
- 9. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, et al. Basal
- 414 insulin and cardiovascular and other outcomes in dysglycemia. Basal insulin and
- cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.
- 416 10. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin
- in stable cardiovascular disease. N Engl J Med. 2017;377:1319-1330.
- 418 11. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after
- Embolic Stroke of Undetermined Source. N Engl J Med. 2018;378:2191-2201.
- 420 12. Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in
- 421 Persons without Cardiovascular Disease. N Engl J Med. 2016;374:2032-2043.
- 422 13. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular
- dementia in developing countries: prevalence, management, and risk factors. Lancet
- 424 Neurol. 2008;7:812-26.
- 425 14. EuroQol Group. EuroQol--a new facility for the measurement of health-related
- 426 quality of life. Health Policy. 1990;16:199-208.
- 427 15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method
- 428 for grading the cognitive state of patients for the clinician. J Psychiatr Res.
- 429 1975;12:189-98.
- 430 16. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive
- 431 Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am
- 432 Geriatr Soc. 2005;53:695-9.
- 433 17. Dong Y, Koay WI, Yeo LL, Chen CL, Xu J, Seet RC, Lim EC. Rapid Screening
- 434 for Cognitive Impairment in Parkinson's Disease: A Pilot Study. Parkinsons Dis.
- 435 2015;2015:348063.

- 18. Spence J, Bosch J, Chongsi E, et al. Standardized Assessment of Global activities
- in the Elderly scale in adult cardiac surgery patients. Br J Anaesth. 2021;127:539-546.
- 438 19. Yang H, Yim D, Park MH. Converting from the Montreal Cognitive Assessment
- to the Mini-Mental State Examination-2. PLoS One. 2021;16:e0254055.
- 20. Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination
- 441 (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and
- over in community and primary care populations. Cochrane Database Syst Rev.
- 443 2016:CD011145.
- 21. Davis DH, Creavin ST, Yip JL, Noel-Storr AH, Brayne C, Cullum S. Montreal
- Cognitive Assessment for the detection of dementia. Cochrane Database Syst Rev.
- 446 2021;7:CD010775.
- 22. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained
- 448 using two criteria based on the receiver operating characteristic curve. Am J
- 449 Epidemiol. 2006;163:670-5.
- 450 23. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention,
- and care: 2020 report of the Lancet Commission, Lancet, 2020;396:413-446.
- 452 24. Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-
- 453 the-Science Conference statement: preventing alzheimer disease and cognitive
- decline. Ann Intern Med. 2010;153:176-81.
- 455 25. Kivimäki M, Singh-Manoux A, Pentti J, et al. Physical inactivity, cardiometabolic
- 456 disease, and risk of dementia: an individual-participant meta-analysis. BMJ.
- 457 2019;365:11495.
- 458 26. Albanese E, Lombardo FL, Prince MJ, Stewart R. Dementia and lower blood
- 459 pressure in Latin America, India, and China: a 10/66 cross-cohort study. Neurology.
- 460 2013;81:228-35.

- 461 27. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease
- and vascular dementia: association with education. The Rotterdam study. BMJ.
- 463 1995;310:970-3.
- 464 28. Selvamani Y, Arokiasamy P. Association of life course socioeconomic status and
- 465 adult height with cognitive functioning of older adults in India and China. BMC
- 466 Geriatr. 2021;21:354.
- 467 29. Yu X, Zhang W, Kobayashi LC. Duration of Poverty and Subsequent Cognitive
- 468 Function and Decline Among Older Adults in China, 2005-2018. Neurology.
- 469 2021;97:e739-e746.
- 470 30. Paradela RS, Ferreira NV, Nucci MP, et al. Relation of a Socioeconomic Index
- 471 with Cognitive Function and Neuroimaging in Hypertensive Individuals. J Alzheimers
- 472 Dis. 2021;82:815-826.
- 473 31. Okamoto S. Socioeconomic factors and the risk of cognitive decline among the
- elderly population in Japan. Int J Geriatr Psychiatry. 2019;34:265-271
- 475 32. Borland E, Nägga K, Nilsson PM, Minthon L, Nilsson ED, Palmqvist S. The
- 476 Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-
- 477 Based Cohort. J Alzheimers Dis. 2017;59:893-901.
- 478 33. Chandra V, Ganguli M, Ratcliff G, et al. Studies of the epidemiology of dementia:
- comparisons between developed and developing countries. Aging Milano 1994; 6:
- 480 307–21.
- 481 34. O'Driscoll C, Shaikh M. Cross-Cultural Applicability of the Montreal Cognitive
- 482 Assessment (MoCA): A Systematic Review. J Alzheimers Dis. 2017;58:789-801.
- 483 35. Tan JP, Li N, Gao J, et al. Optimal cutoff scores for dementia and mild cognitive
- 484 impairment of the Montreal Cognitive Assessment among elderly and oldest-old
- Chinese population. J Alzheimers Dis. 2015;43:1403-12.

486 36. Llibre Rodriguez JJ, Ferri CP, Acosta D, et al. Prevalence of dementia in Latin 487 America, India, and China: a population-based cross-sectional survey. Lancet. 488 2008;372:464-474. 489 37. Magklara E, Stephan BCM, Robinson L. Current approaches to dementia 490 screening and case finding in low- and middle-income countries: Research update and 491 recommendations. Int J Geriatr Psychiatry. 2019;34:3-7. 492 38. Whiteley WN, Anand S, Bangdiwala SI, et al. Are large simple trials for dementia 493 prevention possible? Age Ageing. 2020;49:154-160. 494 495 496 497

Figure 1. Fitting splines on the association between individual's age and (A) study-standardised or

(B) country-standardised cognitive scores by different world regions. Box plot illustrate the median,

interquartile range and range of scores in the whole study population.

(STD: standardised; NA: North America; SA: South America; EE: Eastern Europe; EAsia: East Asia;

SAsia: South Asia; W.Asia: West Asia)

Figure 2. Mean differences in study-standardised or country-standardised baseline cognitive and

functional test scores between the North America, Oceania and Western Europe group and other

world regions, adjusted for individual participant characteristics and centre of recruitment.

(SAGEA: Standardised Assessment of Global activities in the Elderly; NA: North America; SA:

South America; EE: Eastern Europe; EAsia: East Asia; SAsia: South Asia; W.Asia: West Asia)

Figure 3. Estimated prevalence of cognitive impairment in different word regions using absolute

(MMSE ≤24) or MOCA ≤25) or relative thresholds (z-score≤-1.0) based on the study-standardised

or country-standardised mean cognitive test scores. Intraclass correlation coefficient (ICC) is the

proportion variance within clusters over the total variance. (NA: North America; SA: South America;

EE: Eastern Europe; EAsia: East Asia; SAsia: South Asia; W.Asia: West Asia)


Figure 4. Estimated prevalence of functional impairment in different word regions using absolute

(SAGE ≥7) or relative thresholds (z-score≤-1.0) based on the study-standardised or country-

standardised mean functional test scores. Intraclass correlation coefficient (ICC) is the proportion

variance within clusters over the total variance. (NA: North America; SA: South America; EE:

Eastern Europe; EAsia: East Asia; SAsia: South Asia; W.Asia: West Asia)




Baseline Cognitive Score

■ Study standardized ■ Country standardized

medRxiv preprint doi: https://doi.org/10.1101/2023.01.05.2228 **Stutchy vs.co** posted January 7, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Country STD



Baseline SAGEA Score

	Study STD			Country STD	
Region	Mean Diff. (95%CI)	Р		Mean Diff. (95%CI)	Р
N.America/Oceania/W.Europe	Reference			Reference	
S.America	0.03(-0.06, 0.12)	0.508	*	0.04(-0.05, 0.12)	0.385
E.Europe/Russia	0.03(-0.06, 0.12)	0.478	#	0.01(-0.08, 0.09)	0.889
E.Asia	0.23(0.15, 0.32)	<0.001	-	-0.05(-0.13, 0.03)	0.199
S.Asia	-0.16(-0.37, 0.05)	0.136	-	-0.18(-0.37, 0.02)	0.077
Africa	-0.32(-0.59, -0.05)	0.018		-0.10(-0.35, 0.15)	0.44
W.Asia	-0.41(-0.63, -0.19)	<0.001		0.00(-0.21, 0.22)	0.977
		<	-1 -0.5 0 0.5 worse MD (95%CI)better	>	

